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A Causative Relationship Exists Between Eosinophils and the
Development of Allergic Pulmonary Pathologies in the Mouse1
HuaHao H. Shen,*‡ Sergei I. Ochkur,† Michael P. McGarry,† Jeffrey R. Crosby,*
Edie M. Hines,* Michael T. Borchers,† Huiying Wang,*‡ Travis L. Biechelle,* Katie R. O’Neill,*
Tracy L. Ansay,* Dana C. Colbert,† Stephania A. Cormier,† J. Paul Justice,* Nancy. A. Lee,*
and James J. Lee†

A

llergic asthma is a syndrome with marked heterogeneity
characterized by chronic immune-mediated responses in
the lung, leading to airway changes (e.g., mucus hypersecretion and airway epithelial pathology) and pulmonary dysfunction (e.g., reversible airflow limitations and airway hyperresponsiveness (AHR)2) (1, 2). Despite differences occurring in underlying
inflammatory responses and the presentation of symptoms, the presence of eosinophils in the airway mucosa and lumen has been
recognized even in the earliest studies (see, for example, Ref. 3) as a
defining feature of this syndrome (70 –90% of reported cases (4)).
This pulmonary eosinophilia correlates with the histopathological
changes occurring in asthma patients and is associated with the
development of lung dysfunction even in mild cases (4, 5). The
implicit conclusion of these correlative studies is that airway pathology is a concomitant consequence of allergen-induced pulmonary eosinophilia.
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Mouse models of allergic respiratory inflammation have also
contributed to the hypothesis that allergen-induced pulmonary eosinophilia is linked to the onset/progression of lung pathology.
Knockout models deficient of IL-5 and “conditional knockouts”
using anti-IL-5 Abs have been particularly informative. These
studies have demonstrated that allergen-mediated pulmonary pathologies also correlate with an induced pulmonary eosinophilia,
including airway mucus accumulation (6, 7) and AHR (8 –10).
However, defining a causative relationship between allergen-induced eosinophilia and pulmonary pathologies in the mouse has
remained an elusive goal. Moreover, numerous studies have attempted to disassociate these phenomena. For example, studies
have suggested that CD4⫹ T cells, and not eosinophils, are causatively linked to airway histopathology (e.g., airway mucus accumulation (11)). In addition, the lack of a relationship between eosinophils, airway mucus, and development of AHR was also
shown in a study using an ␣4-integrin antagonist (12) and still yet
other studies (see, for example, Refs. 13–17) have attempted to
disassociate allergen-induced pulmonary eosinophilia from lung
dysfunction (e.g., AHR). Thus, regardless of the preponderance of
evidence, the relationship between eosinophils and allergen-mediated pulmonary pathologies has remained correlative with ongoing
debates in both humans (see, for example, Ref. 18 vs Ref. 19) and
mice (see, for example, Ref. 8 vs Ref. 16) as to the physiological
relevance of this relationship.
Previous reports assessing immune-mediated inflammatory responses in the mouse have been greatly aided by the availability of
neutralizing Abs or gene knockout animals deficient for a given
inflammatory signal or cell type. Moreover, in combination with
adoptive transfer, these studies have often permitted a determination of the unique role(s) of the signal/cell type by assessing pulmonary inflammation in its presence vs absence. Several experimental limitations have prevented the use of this strategy to assay
0022-1767/03/$02.00
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Asthma and mouse models of allergic respiratory inflammation are invariably associated with a pulmonary eosinophilia; however,
this association has remained correlative. In this report, a causative relationship between eosinophils and allergen-provoked
pathologies was established using eosinophil adoptive transfer. Eosinophils were transferred directly into the lungs of either naive
or OVA-treated IL-5ⴚ/ⴚ mice. This strategy resulted in a pulmonary eosinophilia equivalent to that observed in OVA-treated
wild-type animals. A concomitant consequence of this eosinophil transfer was an increase in Th2 bronchoalveolar lavage cytokine
levels and the restoration of intracellular epithelial mucus in OVA-treated IL-5ⴚ/ⴚ mice equivalent to OVA-treated wild-type
levels. Moreover, the transfer also resulted in the development of airway hyperresponsiveness. These pulmonary changes did not
occur when eosinophils were transferred into naive IL-5ⴚ/ⴚ mice, eliminating nonspecific consequences of the eosinophil transfer
as a possible explanation. Significantly, administration of OVA-treated IL-5ⴚ/ⴚ mice with GK1.5 (anti-CD4) Abs abolished the
increases in mucus accumulation and airway hyperresponsiveness following adoptive transfer of eosinophils. Thus, CD4ⴙ T
cell-mediated inflammatory signals as well as signals derived from eosinophils are each necessary, yet alone insufficient, for the
development of allergic pulmonary pathology. These data support an expanded view of T cell and eosinophil activities and suggest
that eosinophil effector functions impinge directly on lung function. The Journal of Immunology, 2003, 170: 3296 –3305.
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Materials and Methods
Mice
IL-5-deficient (IL-5⫺/⫺) knockout animals on a C57BL/6J background
were a kind gift of M. Kopf (then at the Basel Institute of Immunology,
Basel, Switzerland) (25). Since receiving these animals the mice have been
continuously backcrossed with C57BL/6J mice (⬎10 generations) purchased from The Jackson Laboratory (Bar Harbor, ME). Genotypes of
mice derived from these crosses were determined by PCR of tail DNA,
detecting the presence of the mutant IL-5 allele. Control C57BL/6J mice
were obtained from The Jackson Laboratory, and all procedures were conducted on mice 8 –12 wk of age maintained in ventilated microisolator
cages housed in a specific pathogen-free animal facility. The sentinel mice
within this animal colony were negative for the presence of known mouse
pathogens. Protocols and studies involving animals were conducted in accordance with National Institutes of Health and Mayo Clinic Foundation
guidelines.

Isolation of eosinophils
Peripheral blood eosinophils were isolated from IL-5 transgenic mice
which constitutively express this cytokine exclusively from mature T cells
using an enhancer/promoter construct derived from the mouse CD3␦ gene
(transgenic line: NJ.1638 (Ref. 21)). NJ.1638 mice are maintained on a
C57BL/6J genetic background by continuous backcross (⬎12 generations)
with mice purchased from The Jackson Laboratory. The average circulating eosinophil counts in 4- to 7-mo-old animals are ⬎100,000 eosinophils/
mm3 of blood, representing 50% of total white blood cells. Pure populations of eosinophils for adoptive transfer were recovered as described
earlier (26). Briefly, peripheral blood (tail bleeds or terminal bleeds from
cardiac puncture) was collected into PBS containing 20 U/ml heparin, layered onto a single-step Percoll gradient, and centrifuged (45 min, 2000 ⫻
g) at 4°C. The buffy coat, containing almost exclusively lymphocytes and
eosinophils, was freed of contaminating red blood cells by hypotonic lysis
and eosinophils were isolated by a negative selection strategy, removing B
cells and T cells with Ab conjugated magnetic beads (MACS, Miltenyi
Biotec, Auburn, CA) specific for CD45-R (B220) and CD90 (Thy 1.2),

respectively. The remaining cells were washed twice with RPMI 1640 and
resuspended in PBS, maintaining these leukocytes at 4°C before use. The
purity of the recovered eosinophils was determined by visual examination
of DiffQuick stained cytospin preparations and was typically ⬎98.5%
(monocytes (0.5%) and neutrophils (1%) comprise the contaminating cell
populations). Eosinophil viability was determined by trypan blue exclusion
and was always ⬎99.6%. Assessments of chemotaxis and morphological
characterizations of the recovered eosinophils revealed that the isolation
was not accompanied by eosinophil activation (see, for example, Ref. 26).
The eosinophils purified from NJ.1638 mice did not display levels of chemotaxis significantly different relative to eosinophils from unpurified white
blood cell preparations, they generated very little to no reactive oxygen
species, and displayed electron microscopic profiles consistent with intact
resting cells (i.e., no evidence of degranulation or changes in granule morphology, including release of major basic protein (MBP), was observed).

OVA sensitization/aerosol challenge and intratracheal (IT)
transfer of eosinophils
Mice were sensitized and challenged with chicken OVA as previously
described (27). Briefly, mice were sensitized by an i.p. injection (100 l)
of 20 g chicken OVA (Sigma-Aldrich, St. Louis, MO) emulsified in
Imject alum (2.25 mg Al(OH)3/2 mg Mg(OH)2) (Pierce, Rockfield, IL) on
days 0 and 14. Mice were subsequently challenged with an aerosol generated from 1% OVA in saline (OVA), or saline alone, for 20 min by
ultrasonic nebulization (DeVilbiss, Somerset, PA) on days 24, 25, and 26.
The mice were assessed for pulmonary cellular infiltrates, histopathologies,
bronchoalveolar lavage (BAL) cytokine levels, and lung function on
day 28.
The adoptive transfer of eosinophils and/or vehicle control (PBS) into
the lungs of mice was accomplished in subject animals lightly anesthetized
with Ketamine-HCL (40 g/gram body weight; Ketaset Fort Dodge Animal Health, Fort Dodge, IA) before IT instillation. Anesthetized animals
were placed in a holder physically supporting the mice in an upright position. The trachea was cleared by holding the tongue to one side with a
pair of forceps and a suspension of eosinophils (107 eosinophils/20 l) was
instilled (alternatively 105 eosinophils/20 l were instilled in some experiments); control animals received 20 l of PBS, using a gel loading pipettetip (Finepoint LTS (catalog no. RT-L10F) Rainin Instrument, Woburn,
MA). A time line of these experimental manipulations is presented in Fig.
1, including both the OVA sensitization/challenge and adoptive transfer
schedules. On the days that mice received both an OVA aerosol challenge
and an IT instillation (i.e., days 24, 25, and 26) these procedures were
staggered with the OVA aerosol challenge occurring in the morning and
the instillation occurring the same day, generally 4 – 6 h later.

Cytokine assays
Cytokine levels in BAL fluid were determined by ELISA. Mouse IFN-␥,
IL-4, IL-5, and IL-13 levels were assessed using immunoassay kits (R&D
Systems, Minneapolis, MN) as per the manufacturer’s instructions. The
limits of detection for each cytokine assay were 5–10 pg/ml.

Ab-mediated neutralization of IL-5 or depletion of CD4⫹ T cells
Additional groups of OVA-treated IL-5⫺/⫺ mice were also administered
either rat anti-mouse IL-5 (TRFK-5 (28)) or rat anti-mouse CD4 (GK1.5
(29)) before IT instillation of eosinophils.
Administration of anti-IL-5 mAbs. TRFK-5 was administered using an
experimental protocol that abolishes both the pulmonary eosinophilia and
the AHR occurring in OVA-treated wild-type mice. TRFK-5 was administered systemically (i.e., i.p. injection of 100 g) as well as locally (i.e.,
intranasal (i.n.) administration of 50 g in 30 l of saline) into lightly

FIGURE 1. Time line representation of the OVA protocol used and the
IT adoptive transfer of eosinophils.
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directly the significance of the induced pulmonary eosinophilia in
allergen challenge models. These limitations include the lack of
uniquely eosinophil-deficient mice and experimental strategies to
isolate and adoptively transfer large numbers of eosinophils into
syngeneic mice. The creation of IL-5⫺/⫺ mice, and/or the use of
anti-IL-5 Abs, have provided model systems that are nearly devoid
of eosinophils. Thus, the loss of allergen-mediated pathologies in
IL-5-deficient animals appears to link eosinophils to the development of these pulmonary pathologies. However, strategies targeting IL-5 to ablate eosinophils have inherent ambiguities because of
activities this cytokine has on other cell types, including B cells
(20), T cells (7, 21–23), and, potentially, airway smooth muscle
activity (24). That is to say, is the loss of allergen-induced pathology in IL-5-deficient mice a consequence of effects on eosinophils
and/or effects on these other IL-5 responsive cells? Nonetheless,
despite this limitation, the availability of an eosinophil adoptive
transfer strategy in the mouse would permit the restitution of a
pulmonary eosinophilia in IL-5⫺/⫺ mice and, in turn, possibly
identify a causative link between the presence of pulmonary eosinophils and allergen-mediated pathologies. To this end, a strategy to isolate and adoptively transfer eosinophils was developed
that uses an IL-5 transgenic mouse line (NJ.1638 (Ref. 21)) as the
source of eosinophils and syngeneic IL-5⫺/⫺ mice as the adoptive
transfer recipients. The data demonstrate that the transfer of eosinophils into IL-5⫺/⫺ mice restores pulmonary eosinophilia (i.e.,
in both the airway lumen and peribronchial areas) to wild-type
levels and results in the recovery of allergic respiratory pathologies. Significantly, allergen-treated recipients depleted of CD4⫹ T
cells failed to develop pulmonary pathologies following eosinophil
adoptive transfer. Thus, these data reveal a synergy between CD4⫹
T cells and eosinophils, both of which are required, but alone are
insufficient, for the development of the pathologies associated with
allergic respiratory inflammation.
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anesthesized animals on day 23 of the OVA protocol described in Fig. 1.
In addition, 2 h before each OVA airway challenge (and ⬃6–8 h before IT
instillation of eosinophils) TRFK-5 was administered i.n. on days 24, 25,
and 26. On day 27, ⬃6–8 h before IT instillation of eosinophils, a final i.n.
dose of TRFK-5 was administered. Control groups of animals received
nonspecific rat IgG (Sigma-Aldrich).
Administration of anti-CD4 mAbs. CD4⫹ cells were depleted from
OVA-treated IL-5⫺/⫺ mice using a protocol first described by Gavett et al.
(30). GK1.5 was administered via the peritoneal cavity (0.5 mg/100 l),
control groups received nonspecific rat IgG, three days before the first
OVA aerosol challenge (day 21, Fig. 1).

Assessments of allergic airway inflammation: pulmonary cellular
infiltrates and Ag-induced histopathologies

Determination of AHR in response to methacholine challenge
AHR was assessed by whole-body plethysmography, inducing airflow obstruction with a methacholine aerosol (32, 33). This methodology (Buxco
Electronics, Troy, NY) relies on pressure differences between a chamber
containing conscious/unrestrained mice and a reference chamber to extrapolate minute volume, tidal volume, breathing frequency, and enhanced
pause (Penh). Penh is a dimensionless parameter that is a function of total
pulmonary airflow in mice (i.e., the sum of the airflows in the upper and
lower respiratory tracts) during the respiratory cycle of the animal and
closely correlates with airway resistance as measured by traditional invasive techniques using ventilated animals (33). Dose-response data were
plotted either as raw Penh values or percent baseline Penh vs the log10 of

the methacholine solution (milligrams per milliliter) used to generate the
aerosol.

Statistical analysis
Data presented are the means (⫾SE). Statistical analysis was performed on
parametric data using Student’s t tests with differences between means
considered significant when p ⬍ 0.05.

Results

Adoptive transfer of eosinophils into the lungs of IL-5⫺/⫺ mice
reconstitutes a pulmonary eosinophilia equivalent to wild-type
mice
Previous studies have demonstrated that the IL-5 deficiency associated with IL-5⫺/⫺ mice led to a significant reduction of pulmonary eosinophils (relative to wild-type mice) following allergen
sensitization/challenge, particularly the eosinophilia of the airway
lumen (6, 8 –10). A strategy to restore this pulmonary eosinophilia
was developed to assess the relative contribution of lung eosinophils to pathologic changes occurring in OVA treated mice. An
IL-5 transgenic mouse line constitutively expressing IL-5 from
circulating T cells (line NJ.1638 (Ref. 21)) was used to isolate pure
(⬎98%) populations of mouse peripheral blood eosinophils with
nearly 100% viability. The adoptive transfer protocol used is diagramed in Fig. 1 and includes the IT instillation of 1 ⫻ 107 eosinophils on each of the three aerosol challenge days of the OVA
protocol as well as the day following the last challenge (i.e., adoptive transfer of a total of 4 ⫻ 107 eosinophils). The transfer of this
number of eosinophils was based on the 1–3 ⫻ 107 eosinophils
present in the lungs of OVA-treated wild-type mice as demonstrated in collengase-digested lung preparations (Ref. 34 and our
unpublished data). The BAL data in Fig. 2 show that the adoptive
transfer of eosinophils directly into the airways of OVA-treated
IL-5⫺/⫺ mice increases airway lumen eosinophils to levels equivalent of OVA-treated wild-type mice. The induced BAL eosinophilia following transfer was not dependent on OVA sensitization/
aerosol challenge of the recipient mice, although fewer BAL
eosinophils were consistently observed in naive vs OVA-treated

FIGURE 2. Adoptive transfer of eosinophils into the lungs of IL-5⫺/⫺ mice restores an airway eosinophilia equivalent to OVA-treated wild-type animals.
The eosinophil levels in BAL fluid from wild-type and IL-5⫺/⫺ mice following either a saline or OVA aerosol challenge were compared with naive vs OVA
aerosol challenged IL-5⫺/⫺ mice following IT adoptive transfer of 4 ⫻ 107 eosinophils (Eos7) or PBS vehicle control. Additional control groups shown
include OVA-treated wild-type mice administered anti-IL-5 mAb TRFK-5 (OVA/␣-IL-5), OVA-treated IL-5⫺/⫺ mice concurrently administered TRFK-5
before IT instillation of eosinophils (␣-IL-5/IL-5⫺/⫺ ⫹ OVA ⫹ Eos7), and OVA-treated IL-5⫺/⫺ mice concurrently administered GK1.5 to deplete CD4⫹
T cells before IT instillation of eosinophils (␣-CD4/IL-5⫺/⫺ ⫹ OVA ⫹ Eos7). The eosinophils found in the BAL of each animal cohort are expressed as
the product of the total number of cells recovered and the percentages of eosinophils derived from differentials (Wright’s stained cytocentrifuge preparations) of 300 cells. Data represent mean values ⫾ SE (n ⫽ 5–10 animals/group). ⴱ, p ⬍ 0.05.
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The cellularity of the airspaces was determined by BAL as previously
described (31). Immunohistochemical detection of eosinophils in lung tissue sections (4 m) was performed using a rabbit polyclonal antisera specific for mouse MBP (32). Staining was performed with diaminobenzidineperoxidase detection reagents as described in earlier studies (23, 27, 31).
Histopathologic changes of the airways, including mucus cell content of
the epithelium, were assessed in paraffin-embedded lungs following formalin fixation (lungs were inflated with a fixed volume (0.5 ml) of fixative). Parasagittal sections (4 m) were stained with periodic acid-Schiff’s
reagent and counterstained with hematoxylin/methyl green to assess mucus
production and goblet cell metaplasia. The mucus content of airways
(both proximal and distal) were assessed by brightfield microscopy (n ⫽
5 mice per group) using an image analysis software program (Image
ProPlus, Silver Spring, MD) to derive an airway mucus index that is
reflective of both the amount of mucus per airway and the number of
airways affected (7).

EOSINOPHIL ACTIVITIES MEDIATE ALLERGIC ASTHMA

The Journal of Immunology
IL-5⫺/⫺ animals. In addition, the resultant BAL eosinophilia did
not occur as a consequence of the adoptively transferred wild-type
eosinophils reconstituting IL-5 in the knockout mice. Coadministration of anti-mouse IL-5 mAb (TRFK-5) had no effect on the
BAL eosinophilia of OVA-treated IL-5⫺/⫺ mice. Moreover, the
depletion of CD4⫹ cells in OVA-treated IL-5⫺/⫺ mice also failed
to affect the BAL eosinophilia induced following adoptive transfer.
The distribution of tissue eosinophils in the lungs of mice following adoptive transfer was determined by immunohistochemistry using a rabbit anti-mouse MBP polyclonal antisera (32). In
addition to confirming the significant loss of tissue eosinophils in
OVA-treated IL-5-deficient mice (i.e., either Ab depleted wildtype or IL-5 knockout) relative to OVA-treated wild-type animals,
these data demonstrate that IT instillation of eosinophils into
OVA-treated IL-5⫺/⫺ mice reconstitutes the peribronchial eosinophilia occurring in OVA-treated wild-type animals (Fig. 3). The
distribution of tissue eosinophils following adoptive transfer was

equivalent to the pattern observed in OVA-treated wild-type mice
with the exception of a smaller, yet significant, perivascular eosinophilia. The identity of these tissue eosinophils as originating from the
adoptive transfer was demonstrated by ex vivo labeling the eosinophils with a fluorescent tag before IT instillation (data not shown).
Quantitative assessments of peribronchial eosinophils surrounding
individual airways in each group of mice are shown in Fig. 4. Tissue
eosinophil accumulation was not dependent on OVA sensitization/
aerosol challenge although tissue eosinophil numbers in naive mice
were consistently lower than OVA-treated IL-5⫺/⫺. These data show
that the adoptive transfer of eosinophils into OVA-treated IL-5⫺/⫺
mice reconstituted eosinophil levels to those observed in wild-type
animals. Moreover, this tissue eosinophilia did not occur as a
consequence of reconstituting IL-5 in the knockout mice. In
addition, the depletion of CD4⫹ cells in OVA-treated IL-5⫺/⫺
mice resulted in a nominal, yet significant, decrease in the
observed tissue eosinophilia occurring after adoptive transfer.
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FIGURE 3. Adoptive transfer of eosinophils into
the lungs of IL-5⫺/⫺ mice results in a pulmonary
tissue eosinophilia equivalent to the spatial distribution of eosinophils in OVA-treated wild-type animals. The accumulation of eosinophils to the lungs
of wild-type and IL-5⫺/⫺ mice was assessed by immunohistochemistry using a rabbit polyclonal antisera specific for mouse MBP (32). The photographs
on the left of each panel are low magnification views
of the lung parenchyma. The photographs on the
right of each panel are representative examples at
high magnification of the eosinophil accumulation
typically found in peribronchial areas. A, OVA sensitized/challenged mice (wild-type OVA); B, OVA
sensitized/challenged IL-5 knockout mice (IL-5⫺/⫺
⫹ OVA); C, Naive IL-5⫺/⫺ mice following IT transfer of eosinophils (Naive IL-5⫺/⫺ ⫹ Eos7), D, OVAtreated IL-5⫺/⫺ mice following IT transfer of eosinophils (IL-5⫺/⫺ ⫹ OVA⫹Eos7). Bars ⫽ 100 m.
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OVA-induced airway epithelial mucus production is dependent,
in part, on the presence of pulmonary eosinophils
An often overlooked consequence of manipulating in vivo IL-5
levels during allergen challenge is a significant change in airway
mucus production (6, 7). These changes in airway epithelial mucus
production are evident in either OVA-treated wild-type mice administered TRFK-5 or OVA-treated IL-5⫺/⫺ mice. In both cases,
airway mucus accumulation decreased ⬃50% relative to OVAtreated wild-type animals (Figs. 5 and 6). IT instillation of eosinophils into OVA-treated IL-5⫺/⫺ mice (restoring pulmonary eosinophil numbers to wild-type levels) eliminates this decrease in
airway epithelial mucus such that no differences are observed relative to OVA-treated wild-type mice (Figs. 5 and 6). This recovery
of airway mucus was dependent on the restitution of pulmonary
eosinophils to wild-type levels. The partial restitution occurring
following transfer of 4 ⫻ 105 eosinophils, which nonetheless induced an airway and tissue eosinophilia ⬃10 times OVA-treated
IL-5⫺/⫺ mice (0.58 ⫾ 0.19 ⫻ 104 vs 0.07 ⫾ 0.03 ⫻ 104, respectively), was insufficient to recover the mucus production observed
in OVA-treated wild-type mice (Fig. 5). The induction of airway
epithelial mucus was not a nonspecific consequence of instilling
eosinophils into the lungs of IL-5⫺/⫺ mice. The instillation of
eosinophils into naive IL-5⫺/⫺ had no effect on mucus production
despite the enormous BAL and peribronchial eosinophilia induced
in these mice (Fig. 6). Interestingly, the increases in intracellular
epithelial mucus following eosinophil adoptive transfer into OVAtreated IL-5⫺/⫺ mice were accompanied by increases in BAL Th2
cytokine levels (Fig. 7). These eosinophil-induced changes included the appearance of airway IL-5, a significant increase in
BAL IL-4 levels (relative to OVA-treated IL-5⫺/⫺ mice), and an
increase in BAL IL-13 levels. IFN-␥ levels remained below detection limits in all the control/experimental groups examined. The
eosinophil-associated induction of mucus, however, was not dependent on the elaboration of IL-5 levels in IL-5⫺/⫺ mice as concurrent administration of TRFK-5 to OVA-treated IL-5⫺/⫺ animals had no effects on the mucus index (Fig. 6). Significantly, the
recovery of intracellular epithelial mucus accumulation following
adoptive transfer of eosinophils did not occur in OVA-treated IL5⫺/⫺ mice depleted of CD4⫹ T cells (Fig. 6). These data demonstrate that both eosinophils and OVA-induced inflammatory signals mediated by CD4⫹ T cells are each necessary to achieve the

airway epithelial mucus levels observed in OVA-treated
wild-type mice.
The AHR associated with OVA sensitization/aerosol challenge
requires both eosinophils and CD4⫹ T cells
The potential role(s) of eosinophils in the development of OVAinduced AHR to methacholine provocation was assessed by
whole-body plethysmography. The resulting dose response curves
(means of single-animal measurements) are presented in Fig. 8.
These data compare the responses of wild-type and IL-5⫺/⫺ mice
with responses occurring in IL-5⫺/⫺ mice following adoptive
transfer of eosinophils. The dose response curves confirm earlier
studies (see, for example, Ref. 8) and demonstrate the loss of AHR
in OVA-treated IL-5⫺/⫺ mice (i.e., no significant differences were
observed in the response of OVA-treated IL-5⫺/⫺ mice and either
saline-treated wild-type or IL-5⫺/⫺ animals). However, this pathophysiologic response was recovered in OVA-treated IL-5⫺/⫺ mice
following the restitution of the pulmonary eosinophilia by adoptive
transfer. The recovery of AHR was restricted to recipient mice that
were OVA sensitized/challenged and did not occur in salinetreated IL-5⫺/⫺ animals (i.e., the presence of pulmonary eosinophils is necessary but not sufficient to induce AHR). In addition,
the recovery of AHR was restricted to OVA-treated mice in which
the pulmonary eosinophilia was restored to OVA-treated wild-type
levels and did not occur following partial restitution of the eosinophilia (Fig. 9). The concurrent administration of anti-IL-5 Ab had
no measurable effect on the AHR that occurs in OVA-treated IL5⫺/⫺ mice following eosinophil transfer (Fig. 9), demonstrating
that the observed pathophysiology is not a consequence of reconstituting IL-5 in these animals. The data of Fig. 9 also demonstrate
that similar to the induction of OVA-mediated intracellular airway
epithelial mucus accumulation, the recovery of AHR following
adoptive transfer of eosinophils did not occur in OVA-treated IL5⫺/⫺ mice depleted of CD4⫹ T cells thus showing that both eosinophils and CD4⫹ T cells are each necessary, but alone insufficient, to achieve AHR in this model of allergen-mediated
respiratory inflammation.

Discussion
The hypothesis that allergic respiratory pathology is a concomitant
response of the induced pulmonary eosinophilia is based on a large
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FIGURE 4. The pulmonary tissue eosinophilia
following adoptive transfer into IL-5⫺/⫺ mice is
quantitatively equal to the eosinophilia occurring in
OVA-treated wild-type animals. Pulmonary tissue
eosinophils were assessed as a function of peribronchial area (square millimeters). The animal
groups assessed include wild-type and IL-5⫺/⫺
mice following saline or OVA challenge vs naive
and OVA-treated IL-5⫺/⫺ mice following IT instillation of 4 ⫻ 107 eosinophils (Eos7) or PBS vehicle
control. Additional control groups shown include
OVA-treated wild-type mice administered antiIL-5 mAb TRFK-5 (OVA/␣-IL-5), OVA-treated
IL-5⫺/⫺ mice concurrently administered TRFK-5
(IL-5⫺/⫺ ⫹ OVA ⫹ Eos7/␣-IL-5) before IT instillation of eosinophils, and OVA-treated IL-5⫺/⫺
mice concurrently administered GK1.5 to deplete
CD4⫹ T cells before IT instillation of eosinophils
(IL-5⫺/⫺ ⫹ OVA ⫹ Eos7/␣-CD4). The values presented are means (⫾SE) derived from two to five
sections per mouse (n ⫽ 5–7 mice per group).
ⴱ, p ⬍ 0.05.
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body of correlative (i.e., circumstantial) data from both asthma patients and mouse models. However, the advent of a strategy to
specifically introduce eosinophils into the lungs of otherwise eosino-

phil-deficient mice now provides evidence that the allergen-induced
eosinophilia is indeed causatively linked to the development of pulmonary pathology. In particular, eosinophil effector functions in the

FIGURE 6. Restitution of the pulmonary eosinophilia in OVA sensitized/challenged IL-5⫺/⫺ mice restores intracellular airway epithelial mucus accumulation to levels observed in OVA-treated wild-type mice. Mucus accumulation (i.e., Mucus Index) was determined in groups of wild-type and IL-5⫺/⫺
mice following saline or OVA challenge vs naive and OVA-treated IL-5⫺/⫺ mice following IT instillation of 4 ⫻ 107 eosinophils (Eos7) or PBS vehicle
control. Control groups shown include OVA-treated wild-type mice administered anti-IL-5 mAb TRFK-5 (OVA/␣-IL-5), OVA-treated IL-5⫺/⫺ mice
concurrently administered TRFK-5 before IT instillation of eosinophils (IL-5⫺/⫺ ⫹ OVA ⫹ Eos7/␣-IL-5), and OVA-treated IL-5⫺/⫺ mice concurrently
administered GK1.5 to deplete CD4⫹ T cells before IT instillation of eosinophils (IL-5⫺/⫺ ⫹ OVA ⫹ Eos7/␣-CD4). All evaluations of mucus content were
performed in duplicate as independent observer-blinded assessments of five animals per group (two to five sections per animal). ⴱ, p ⬍ 0.05.
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FIGURE 5. Pulmonary eosinophils and CD4⫹ T
cells are each required to achieve the induced airway
mucus accumulation observed in OVA-treated wildtype mice. Lung sections from formalin-fixed/paraffin-embedded tissue were stained for the presence of
mucin with periodic acid-Schiff’s reagent (counterstain: hematoxylin/methyl green). The photographs
presented show representative examples of the staining that occurs in bronchioles. Airways from saline
control (A) and OVA sensitized/challenged wild-type
(B) mice are shown in comparison to similar airways
from OVA sensitized/challenged IL-5⫺/⫺ mice following IT instillation of PBS (C) and OVA sensitized/
challenged IL-5⫺/⫺ mice following IT instillation of
4 ⫻ 105 eosinophils (Eos5) (D) or 4 ⫻ 107 eosinophils
(Eos7) (E). F, OVA-treated IL-5⫺/⫺ mice concurrently administered GK1.5 to deplete CD4⫹ T cells
before IT instillation of eosinophils (IL-5⫺/⫺ ⫹ OVA
⫹ Eos7/␣-CD4). Bar ⫽ 50 m.
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to be established; however, the ability of eosinophils to traverse the
airway epithelium may have a logistical advantage for host defense. The differential movement of eosinophils to the lumen may
permit these cells to encounter pathogens before they violate the

FIGURE 7. Adoptive transfer of eosinophils to the lungs of OVA sensitized/challenged IL-5⫺/⫺ mice results in the appearance of airway IL-5
and increases in BAL IL-4 and IL-13 levels. Cohorts of mice (n ⫽ 5) were
sacrificed on day 28 of the OVA protocol to determine BAL levels of IL-4,
IL-5, and IL-13 in wild-type animals following saline or OVA challenge,
saline and OVA challenged IL-5⫺/⫺ mice following IT instillation of
PBS, and OVA-treated IL-5⫺/⫺ mice following IT instillation of either
4 ⫻ 105 (Eos5) or 4 ⫻ 107 (Eos7) eosinophils. Data represent means ⫾
SE. ⴱ, p ⬍ 0.05.

lung are necessary for allergen-induced airway mucus accumulation
and the development of AHR in response to a cholinergic receptor
agonist.
The IT instillation of peripheral blood eosinophils into the lungs
of IL-5⫺/⫺ mice highlights the ability of these leukocytes to engage in reciprocal movement from the airway lumen and lung
tissue. Specifically, eosinophils in the airway lumen are capable of
traversing the respiratory epithelium. This phenomenon was noted
earlier in an elegant study by Shi et al. (35) who demonstrated that
eosinophils are capable of trafficking from the lumen to draining
pulmonary lymph nodes where they function as APC and activate
T cells. The physiological relevance of this APC function remains

FIGURE 9. Recovery of allergen-induced AHR in IL-5⫺/⫺ mice following eosinophil adoptive transfer is dependent on the extent to which the
pulmonary eosinophilia is restored as well as the presence of CD4⫹ cells.
Airway reactivity (percent baseline Penh) in response to increasing doses
of nebulized methacholine was assessed by whole-body plethysmography
(n ⫽ 10 –12 mice/group). The groups examined include: wild-type OVAtreated mice concurrently administered either nonspecific IgG (ns-IgG) or
TRFK-5 (␣IL-5), OVA-treated IL-5⫺/⫺ mice following IT instillation of
4 ⫻ 105 (Eos5) eosinophils (IL-5⫺/⫺ OVA ⫹ Eos5), and OVA-treated
IL-5⫺/⫺ mice concurrently administered either TRFK-5 or GK1.5 before
IT instillation of 4 ⫻ 107 (Eos7) eosinophils (IL-5⫺/⫺ OVA ⫹ Eos7 ⫹
␣IL-5 and IL-5⫺/⫺ OVA ⫹ Eos7 ⫹ ␣CD4, respectively). ⴱ, p ⬍ 0.05,
(wild-type OVA ⫹ ns-IgG) and (IL-5⫺/⫺ OVA ⫹ Eos7 ⫹ ␣IL-5) vs the
remaining three groups. The baseline Penh values (⫾SE) of the animal
groups examined are: wild-type OVA-treated mice administered ns-IgG,
0.30 ⫾ 0.01; wild-type OVA-treated mice administered anti-IL-5, 0.33 ⫾
0.01; IL-5⫺/⫺ OVA-treated mice following IT instillation with 4 ⫻ 105
eosinophils, 0.39 ⫾ 0.08; IL-5⫺/⫺ OVA-treated mice administered antiIL-5 following IT instillation with 4 ⫻ 107 eosinophils, 0.33 ⫾ 0.04; IL5⫺/⫺ OVA-treated mice administered ␣CD4 following IT instillation with
4 ⫻ 107 eosinophils, 0.34 ⫾ 0.02.
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FIGURE 8. Pulmonary eosinophils are necessary but not sufficient to
induce allergen-mediated AHR. Methacholine dose-response curves result
from group mean data (⫾SE) of 10 –12 mice/group. Airway reactivity
(Penh) in response to increasing doses of nebulized methacholine was assessed by whole-body plethysmography. The data are presented side by
side in two separate plots for clarity: saline vs OVA treatment of wild-type
and IL-5⫺/⫺ mice and saline vs OVA treated IL-5⫺/⫺ mice administered
either 4 ⫻ 107 eosinophils (Eos7) or PBS vehicle control. ⴱ, p ⬍ 0.05,
(wild-type OVA) vs (wild-type saline) and (IL-5⫺/⫺ OVA ⫹ Eos7) vs
(IL-5⫺/⫺ OVA ⫹ PBS).
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served increase in BAL Th2 cytokine levels following eosinophil
transfer into OVA-treated IL-5⫺/⫺ recipients may be representative of
either mechanism as eosinophils themselves have the potential to
elaborate Th2 cytokine levels (37) as well as the ability to regulate
Th2 cytokine (e.g., IL-13) production by T cells (38). These effects,
particularly within localized microenvironments within the lung,
therefore have the potential to induce/enhance mucus production (as
well as AHR (39)) in such a way as to give the appearance that these
phenomena are elicited by T cells alone.
Several important insights regarding eosinophil activities and
the onset/progression of pulmonary pathologies are apparent, and
worth noting, despite the unresolved issues surrounding specific
effector functions: 1) Eosinophils alone are insufficient to elicit
either mucus accumulation or AHR (i.e., transfer of eosinophils
into naive IL-5⫺/⫺ had no affect on either pathology), suggesting
that the inflammatory process provides one or more signals leading
to the execution of eosinophil effector functions. 2) The loss of
IL-5 activities in OVA-treated IL-5⫺/⫺ mice, which resulted in
both a significant decrease in mucus accumulation and AHR, were
recoverable (i.e., equivalent to wild-type levels) following adoptive transfer of eosinophils (Note: the effects on AHR are likely
also to be quantitative and not absolute, but the small size of the
changes, and the methodology used, preclude statistically significant assessments). Thus, IL-5 activities appear to be restricted to
effects on eosinophils in this mouse model and not the additional
cell types that have been implicated as potential targets of IL-5
(e.g., B cells (20), T cells (7, 22, 23), and airway smooth muscle
(24)). Further support for this conclusion is provided by our demonstration that the selective ablation of eosinophils in the lung,
without concurrent effects on T cell activities, also leads to the
attenuation of airway mucus and the loss of AHR (40). The specific function(s) of IL-5 on eosinophils remain unresolved as these
effects may be a consequence of either an IL-5 proliferative capacity inducing pulmonary eosinophilia, a regulative capacity necessary for eosinophil activation, or the additional possibility that
IL-5 is required for the recruitment of these leukocytes from circulation (6). 3) Potential contributions of eosinophils to pulmonary
pathologies were dependent on the presence of CD4⫹ T cells. This
phenomenon has also recently been described in a study showing
that eosinophil associated lung tissue damage in a helminth infestation model system was dependent on the presence of CD4⫹ T
cells (41). Thus, it appears that signaling between these cells (either directly or through third party intermediates) is necessary for
the activation of one or both cell types, and the execution of eosinophil effector functions in vivo. This signaling may occur
through direct cell-cell interactions or in trans through the release
of soluble factors. The demonstrated APC function of eosinophils
provides a mechanism by which direct cell-cell interactions may
lead to eosinophil activation. Significantly, these interactions are
not necessarily limited to MHC-TCR mediated events. The demonstration that eosinophils also express costimulatory cell-surface
receptors, such as CD28 and CD86 (42), suggests that multiple
receptor-ligand interactions are possible between eosinophils and
T cells that may result in signaling cascades in one or both cell
types that ultimately leads to the recruitment, activation, and/or the
execution of eosinophil effector functions. However, this cell-cell
interaction paradigm requires physical contact between T cells and
eosinophils. An alternative possibility, with potentially less restrictions, is a model in which interactions with eosinophils are mediated
by a soluble factor secreted by T cells or a third party cell. Pulmonary
basophils/mast cells may represent a potential third party cell. However, the observation that the restitution of the pulmonary eosinophilia
in OVA-treated IL-5⫺/⫺ mice was not accompanied by significant
changes in the number, location, or histological morphology of
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integrity of the airway epithelium. Presumably these interactions
are part of strategies to kill and/or expel these invading microorganisms, and in doing so, eosinophils would be able to ferry Ags
back to sites of T cell maturation (i.e., pulmonary lymph nodes),
enhancing acquired immune responses. This model does not prevent the reciprocal movement of eosinophils (i.e., from the interstitium to the lumen and then back to the interstitium) from also
having an additional functional significance. For example, the execution of eosinophil effector functions may be linked to this reciprocal movement. That is, eosinophils which traffic to the airway
lumen in response to allergen-mediated inflammation would receive signals and/or interactions in this milieu that elicit activation,
resulting in their subsequent recruitment back to the lung interstitium/pulmonary lymphatic circulation, and ultimately the execution of effector functions leading to pulmonary pathology.
The eosinophil dependence of allergen-induced AHR and airway mucus accumulation suggests that effector functions have
multiple effects in the lung which are physiologically relevant. The
link between eosinophils and AHR, in particular, has been difficult
to establish as studies abound both supporting and opposing the
null hypothesis. Studies which demonstrate that AHR occurs in the
absence of a significant airways eosinophilia (see, for example,
Refs. 13–17) have been uniquely problematic. However, these
studies have a significant limitation, they define causation of pathologies as independent of eosinophils because in some model
systems the pathologies occur in the absence of this cell. An alternative explanation is that AHR is a complex response resulting
from multiple, and potentially independent, mechanisms. Thus, eosinophil-dependent and -independent pathways leading to AHR
likely exist and thus under some experimental conditions AHR
may still occur in the absence of this cell. The conflict in the
literature regarding the background strain dependency of AHR in
IL-5⫺/⫺ mice (Ref. 8 vs Ref. 16), and, in turn, the unique contribution of eosinophils to AHR, may be a consequence of the differential importance of these multiple pathways in various strains
of mice (i.e., eosinophils contribute to AHR in all strains but in
some strains eosinophil dependent pathways are prominent
whereas in others they are not).
The logistics surrounding eosinophils and airway mucus accumulation are clearly more complex as the development of this
histopathology appears unrelated to the presence or absence of
pulmonary eosinophils (11, 36). In fact, many studies have suggested that airway mucus accumulation is linked only with CD4⫹
T cells and not eosinophils (see, for example, Ref. 11). However,
the hegemony of CD4⫹ T cells may have obscured the quantitative
dependence of airway mucus production on the presence of eosinophils. These previous studies showed that airway mucus production was possible in the absence of eosinophils, but did not demonstrate that eosinophils have no role in this histopathology.
Indeed, the conclusion that eosinophils quantitatively contribute to
allergen-mediated mucus production is consistent with the observation that although mucus production still occurred in OVAtreated IL-5⫺/⫺ mice, it occurs at levels significantly lower than
either OVA-treated wild-type mice or OVA-treated IL-5⫺/⫺ animals following adoptive transfer of eosinophils. These observations imply that multiple pathways contribute to goblet cell metaplasia/mucus production following allergen provocation, including
eosinophil-independent and -dependent pathways. It is noteworthy
that potential mechanisms of eosinophil-dependent contributions
to mucus production, as well as eosinophil-dependent AHR, are
not exclusive of T cell mediated activities. This observation leaves
open the possibilities that T cells elicit eosinophil effector functions
which contribute to pulmonary pathologies or that eosinophils induce
additional T cell-mediated activities augmenting pathology. The ob-
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pulmonary basophil/mast cells (data not shown) suggests that this
unlikely although the specific role(s) of these cells remains to be
defined. In contrast, many other potential T cell-dependent signals
exist that are known to have effects on eosinophil activities, including the expression of IL-4/IL-13 (38, 43), small molecule lipid
intermediates (e.g., leukotrienes or PAF (44 – 46)), and CCR3 chemokine ligands such as eotaxin (reviewed in Ref. 47). Each of
these mechanisms also need not be mutually exclusive, and are all
likely to occur as part of allergen-mediated inflammatory responses in the lung. Regardless of the eventual identification of the
mechanism(s) mediating this interaction and the definition of specific eosinophil effector functions, the data support an expanded
view of eosinophil activities in the lung and suggest that this cell
is part of a pathway(s) underlying allergic respiratory inflammation and lung dysfunction.
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